Antimicrobials

  • P. N. Patsalos
Chapter

Abstract

Phenobarbital Phenobarbital enhances the metabolism of chloramphenicol and can decrease plasma chloramphenicol levels by 70–95 % 1.

Keywords

Carbamazepine Zidovudine Itraconazole Lamotrigine Phenobarbital 

References

  1. 1.
    Bloxham RA, Durbin GM, Johnson T, Winterborn MH. Chloram­phenicol and phenobarbitone – a drug interaction. Arch Dis Childhood. 1979;54:76–7.CrossRefGoogle Scholar
  2. 2.
    Krasinski K, Kusmiesz H, Nelson JD. Pharmacologic interactions among chloramphenicol, phenytoin and phenobarbital. Pediatr Infect Dis. 1982;1:232–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ. Drug interactions with clinafloxacin. Antimicrob Agents Chemother. 2001;45:2543–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Penttila O, Neuvonen PJ, Aho K, Lehtovaara R. Interaction between doxycycline and some antiepileptic drugs. Br Med J. 1974;2:470–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Neuvonen PJ, Penttila O, Lehtovaara R, Aho K. Effects of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol. 1975;9:147–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Acocella G, Bonollo L, Mainardi M, Margaroli P, Nicolis FB. Kinetic studies on rifampicin. III. Effect of phenobarbital on the half-life of the antibiotic. Tijdschr Gastroenterol. 1974;17:151–8.PubMedGoogle Scholar
  7. 7.
    Eradiri O, Jamali F, Thomson ABR. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn’s disease. Biopharm Drug Dispos. 1988;9:219–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Reigelman S, Rowland M, Epstein WL. Griseofulvin-phenobarbital interaction in man. J Am Med Assoc. 1970;213:426–31.CrossRefGoogle Scholar
  9. 9.
    Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther. 1991;49:420–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, Pappagianis D, Stevens DA. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavendier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf. 1993;9:309–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than 10-fold by phenytoin. Clin Pharmacol Ther. 1995;58:617–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin. 2007;23:1415–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration or voriconazole and phenytoin: pharmacokinetic interaction, safety, and tolerance. Br J Clin Pharmacol. 2003;56 (Suppl 1):37–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Lanchote VL, Garcia FS, Dreossi SAC, Takayanagui OM. Pharma­cokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit. 2002;24:338–45.PubMedCrossRefGoogle Scholar
  16. 16.
    Luder PJ, Siffert B, Witassek F, Meister F, Bircher J. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31:443–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Bittencourt PRM, Garcia CM, Martins R, Fernandes AG, Dieckmann HW, Jung W. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology. 1992;42:492–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa. A double drug interaction. N Engl J Med. 1982;307:1325–7.PubMedCrossRefGoogle Scholar
  19. 19.
    DiCenzo R, Peterson DR, Cruttenden K, Mariuz P, Rezk NL, Hochreiter J, Gelbard H, Schifitto G. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother. 2008;52:3035–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Dasgupta A, Okhuysen PC. Pharmacokinetic and other interactions in patients with AIDS. Ther Drug Monit. 2001;23:591–605.PubMedCrossRefGoogle Scholar
  21. 21.
    Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48:948–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Robertson SM, Penzak SR, Lane J, Pau AK, Mican JM. A potential significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin Infect Dis. 2005;41:e15–8.PubMedCrossRefGoogle Scholar
  23. 23.
    DiCenzo R, Peterson DR, Cruttenden K, Morse G, Riggs G, Gelbard H, Schifitto G. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4328–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Hugen PWH, Burger DM, Brinkman K, ter Hofstede HJM, Schuuman R, Koopmans PP, Hekster YA. Carbamazepine-indinavir interaction causes antiretroviral failure. Ann Pharmacother. 2000;34:465–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Langdon G, Davis J, Layton G, Chong C, Weissgerber G, Vourvahis M. Effects of ketoconazole and valproic acid on the pharmacoki­netics of the next-generation NNRTI lersivirine (UK-453,061) in healthy adult subjects. Br J Clin Pharmacol. 2012;73(5):768–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Van der Lee MJ, Dawood L, ter Hofstede HJM, de Graaff-Teulen MJA, van Ewijk-Beneken-Kolmer EWJ, Caliskan-Yassen N, Koopmans PP, Burger DM. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy volunteers. Clin Pharmacol Ther. 2006;80:159–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol. 1990;47:640–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36(5):1034–40.PubMedCrossRefGoogle Scholar
  29. 29.
    L’Homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce the elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr. 2006;43:193–6.PubMedCrossRefGoogle Scholar
  30. 30.
    van Luin M, Colbers A, Verwey-van Wissen CP, van Ewijk-Beneken-Kolmer EW, van der Kolk M, Hoitsama A, da Silva HG, Burger DM. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol. 2009;49:1220–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56:526–36.PubMedCrossRefGoogle Scholar
  32. 32.
    Kellinghaus C, Engbrine C, Kovac S, Moddel G, Boesebeck F, Fischera M, Anneken K, Klonne K, Reichelt D, Evers S, Husstedt IW. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008;17:27–33.PubMedCrossRefGoogle Scholar
  33. 33.
    Burger DM, Meenhorst PL, Mulder JW, Kraaijeveld CL, Koks CH, Bult A, Beijnen JH. Therapeutic drug monitoring of phenytoin in patients with acquired immunodeficiency syndrome. Ther Drug Monit. 1994;16:616–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE, Agrawal KC. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1994;56:272–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations